Genetic testing for inherited eye conditions in over 6,000 individuals through the eyeGENE network
Affiliations
- PMID: 32893963
- DOI: 10.1002/ajmg.c.31843
Abstract
Genetic testing in a multisite clinical trial network for inherited eye conditions is described in this retrospective review of data collected through eyeGENE®, the National Ophthalmic Disease Genotyping and Phenotyping Network. Participants in eyeGENE were enrolled through a network of clinical providers throughout the United States and Canada. Blood samples and clinical data were collected to establish a phenotype:genotype database, biorepository, and patient registry. Data and samples are available for research use, and participants are provided results of clinical genetic testing. eyeGENE utilized a unique, distributed clinical trial design to enroll 6,403 participants from 5,385 families diagnosed with over 30 different inherited eye conditions. The most common diagnoses given for participants were retinitis pigmentosa (RP), Stargardt disease, and choroideremia. Pathogenic variants were most frequently reported in ABCA4 (37%), USH2A (7%), RPGR (6%), CHM (5%), and PRPH2 (3%). Among the 5,552 participants with genetic testing, at least one pathogenic or likely pathogenic variant was observed in 3,448 participants (62.1%), and variants of uncertain significance in 1,712 participants (30.8%). Ten genes represent 68% of all pathogenic and likely pathogenic variants in eyeGENE. Cross-referencing current gene therapy clinical trials, over a thousand participants may be eligible, based on pathogenic variants in genes targeted by those therapies. This article is the first summary of genetic testing from thousands of participants tested through eyeGENE, including reports from 5,552 individuals. eyeGENE provides a launching point for inherited eye research, connects researchers with potential future study participants, and provides a valuable resource to the vision community.
Keywords: gene therapy; genetic testing; inherited retinal disease; rare eye disease.
Published [2020]. This article is a U.S. Government work and is in the public domain in the USA.
Similar articles
- eyeGENE(R): a novel approach to combine clinical testing and researching genetic ocular disease.Curr Opin Ophthalmol. 2012 Sep;23(5):355-63. doi: 10.1097/ICU.0b013e32835715c9.PMID: 22847030 Free PMC article. Review.
- eyeGENE®: a vision community resource facilitating patient care and paving the path for research through molecular diagnostic testing.Clin Genet. 2013 Aug;84(2):190-7. doi: 10.1111/cge.12193. Epub 2013 Jun 5.PMID: 23662816 Free PMC article.
- Prevalence of mutations in eyeGENE probands with a diagnosis of autosomal dominant retinitis pigmentosa.Invest Ophthalmol Vis Sci. 2013 Sep 19;54(9):6255-61. doi: 10.1167/iovs.13-12605.PMID: 23950152 Free PMC article.
- Molecular diagnostic testing by eyeGENE: analysis of patients with hereditary retinal dystrophy phenotypes involving central vision loss.Invest Ophthalmol Vis Sci. 2014 Jul 31;55(9):5510-21. doi: 10.1167/iovs.14-14359.PMID: 25082885 Free PMC article.
- Molecular Therapies for Choroideremia.Genes (Basel). 2019 Sep 23;10(10):738. doi: 10.3390/genes10100738.PMID: 31548516 Free PMC article. Review.
No hay comentarios:
Publicar un comentario